Shareprice
14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company

Regulatory


March 12, 2024

  • Collaboration within robotics surgery in head and neck cancer

Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field of precision cancer surgery, is pleased to announce a collaboration with Intuitive Surgical, a world leading robotic-assisted surgery company.

FluoGuide is advancing the clinical development of FG001 for surgical guidance of brain cancer surgery, head and neck cancer surgery, and photothermal therapy for brain cancer treatment.

This collaboration agreement is a milestone in the development within head & neck cancer where the aim is to develop FG001 to enable better treatment for patients with cancer.

The objective of the collaboration is to develop FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Intuitive’s technology platforms.

The agreement has no initial payment and is non-exclusive. The terms of this agreement are not disclosed, and the agreement will not have an impact on the FluoGuide result in 2024.

"We are extremely happy about this collaboration agreement with Intuitive, this pioneer within robotic-assisted surgery. Not only does it open for new opportunities through groundbreaking surgical technologies, but it also brings new surgical opportunities for patients with head and neck cancer through less invasive care.” says Morten Albrechtsen, CEO.
 
For further information, please contact:
Morten Albrechtsen, CEO
FluoGuide A/S
Phone: +45 24 25 62 66
E-mail: ma@fluoguide.com
 
Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: ca@skmg.se
 
About Intuitive
Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, with UK and Ireland offices in Oxford, UK, is a global leader in minimally invasive care and a pioneer of robotic-assisted surgery. Intuitive’s ground-breaking technologies include the da Vinci surgical system and the Ion endoluminal system. Digital intelligence allows Intuitive to unite the advanced systems, progressive learning, and value-enhancing services to help physicians and their teams optimize care delivery to support the best outcomes possible. Intuitive envisions a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most. For more information, please visit: https://www.intuitive.com/
 
About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. FG001 binds to the receptor uPAR being extensively expressed on most solid cancer types. The photothermal potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery.

The Company has published strong results from phase II trials demonstrating the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck and lung cancers. Based on this strong foundation, FluoGuide expands the scope of application of FG001 and advance the development toward approval in aggressive brain cancer. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”. Read more about FluoGuide’s pipeline, technology, and upcoming events on www.fluoguide.com